The Rise of a 'Miracle' Medication
First, a quick refresher. GLP-1 receptor agonists are a class of medications that include popular brand names like Ozempic, Wegovy, and Mounjaro. Originally developed for managing Type 2 diabetes, they were found to be incredibly effective for weight
loss. They work by mimicking a gut hormone that tells your brain you're full, slows down digestion, and helps regulate blood sugar. For many, these drugs have been life-changing, quieting the constant 'food noise' and leading to significant weight loss that was previously unattainable. Their popularity has soared, but because they are relatively new as a mass-market weight loss tool, the long-term questions—especially about what happens after treatment ends—are only now being answered.
What the New 80,000-Patient Study Found
A major new study published in The Lancet Regional Health – Europe provides our most significant look yet at this question. Researchers in Italy analyzed the health records of 80,302 people with Type 2 diabetes who were prescribed a GLP-1 medication between 2004 and 2024. Of this large group, a majority—about 60%—had stopped taking the medication by their last check-up. The researchers then compared the health outcomes of those who continued the treatment with those who discontinued it. The results were striking and grabbed headlines immediately.
A Doubled Risk of Major Health Events
The study found that patients with Type 2 diabetes who stopped taking their GLP-1 medication had approximately double the risk of suffering a non-fatal heart attack, a non-fatal stroke, or dying from any cause compared to patients who continued their treatment. This association was even stronger in patients who were also living with obesity. On the surface, this sounds terrifying—as if stopping the drug itself triggers these severe outcomes. However, the most important part of this study is understanding what it can't tell us.
The Crucial Caveat: Association Is Not Causation
This was an observational study, which means it can only identify a link or an association between two things; it cannot prove that one caused the other. Experts have been quick to point this out. It's possible that the people who stopped the medication were already in poorer health, which is why they discontinued treatment in the first place. For example, a patient who becomes seriously ill from another condition might stop taking their GLP-1, and that underlying illness could be the real reason for their increased risk of a heart attack. The study did not track why people stopped, which could be due to cost, side effects, or a new, complicating health issue. Therefore, we can't conclude that withdrawing from the drug causes heart attacks, only that discontinuation is associated with a higher risk in this patient group.
What We Know for Sure: Weight Regain
While the cardiovascular findings are new and warrant more research, there is one outcome of stopping GLP-1s that is well-established: weight regain. Previous clinical trials have consistently shown that when people stop taking these medications, the biological mechanisms that the drugs were suppressing—like appetite and slower digestion—return to normal. One major study found that a year after stopping the medication, patients had regained, on average, two-thirds of the weight they had lost. This reinforces what doctors have been saying for years: obesity is a chronic disease, much like high blood pressure or diabetes itself. The medications manage the condition but do not cure it. When the treatment stops, the disease symptoms often return.
The Realities of Long-Term Treatment
If these drugs are meant for long-term use, why do so many people stop? Discontinuation is very common. Studies show that a large percentage of patients stop within the first year for various reasons. The most common culprits are gastrointestinal side effects like nausea and constipation, the high cost of the medication, and lack of insurance coverage. For many, staying on the treatment indefinitely is simply not feasible. This new Italian study highlights that for those with Type 2 diabetes, stopping the medication may coincide with a return of not just weight, but also cardiovascular risks that the drug was helping to manage.
















